Short- and Long-Term Effects of Whole-Body Photobiomodulation in Type II Diabetes Patients: A Protocol for a Controlled Clinical Trial
Key facts
- Where
- Granada, SpainSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 70 years old?
Source: NCT07047248, who can take part
Where in Spain
- DrGranada, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Malaga
- Trial code
- NCT07047248
- Record updated
- 2 July 2025
- Original description
The development of an integral and global treatment to improve the quality of life in those withType II Diabetes Patients is challenging, thus a whole body Photobiomodulation (PBM) therapy program is proposed as an effective option.Read full original descriptionShow less
The development of an integral and global treatment to improve the quality of life in those withType II Diabetes Patients is challenging, thus a whole body Photobiomodulation (PBM) therapy program is proposed as an effective option.
Inclusion: Adults aged 30 to 70 years; Diagnosed with Type 2 Diabetes Mellitus (T2DM) according to the American Diabetes Association (ADA) criteria; HbA1c levels between 6.5% and 10% at screening; Stable diabetes management regimen (medications and lifestyle) for at least three months prior to enrollment.
Exclusion: Presence of severe diabetic complications (e.g., end-stage renal disease, proliferative diabetic retinopathy); History of photosensitivity or medical conditions exacerbated by light exposure; Use of medications or supplements known to significantly alter glucose metabolism, other than current stable diabetes management; Pregnant or lactating women.